

## CD19 negativní relaps B prekurzorové leukémie po použití cíleného léčiva Blinatumomabu



**MUDr. Ester Mejstříková, Ph.D.,** [Klinika dětské hematologie a onkologie](#) 2. LF UK a FN Motol

CD19-negative relapse in B-cell precursor acute lymphoblastic leukemia (ALL) is observed as an infrequent event after chemotherapy and in up to 20% of patients after CD19-directed chimeric antigen receptor (CAR) T-cell immunotherapy. Patients with CD19-negative relapse usually have a poor prognosis. The mechanisms underlying CD19-negative relapse are not fully understood but are important to elucidate to further optimize CD19-directed immunotherapies. Monitoring blasts in patients with CD19-negative relapse by flow cytometry is challenging due to the lack of cell surface markers other than CD19 that are consistently expressed. Furthermore, CD19 is often used as a parameter to quantify minimal residual disease (MRD) and diagnose relapse. Potential markers to monitor persistent or recurrent leukemic blasts in an emergent CD19-negative blast population include B-cell lineage antigens (CD20, CD22, CD24, and intracellular [i]CD79a) and the common ALL antigen CD10.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802535/>

Vydáno: **1. 3. 2019** / Odpovědná osoba: **Mgr. Ing. Tereza Křstková**

---

**URL zdroje (upraveno 26. 3. 2019 - 10:19):** <https://www.lf2.cuni.cz/fakulta/vyznamne-publikace/cd19-negativni-relaps-b-prekurzorove-leukemie-po-pouziti-cileneho-leciva>